United Therapeutics (UTHR) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

UTHR Stock Forecast


United Therapeutics stock forecast is as follows: an average price target of $358.20 (represents a -4.94% downside from UTHR’s last price of $376.80) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

UTHR Price Target


The average price target for United Therapeutics (UTHR) is $358.20 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $575.00 to $215.00. This represents a potential -4.94% downside from UTHR's last price of $376.80.

UTHR Analyst Ratings


Buy

According to 7 Wall Street analysts, United Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for UTHR stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

United Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Jasper HellwegArgus Research$400.00$362.3610.39%6.16%
Oct 31, 2024Andrew FeinH.C. Wainwright$425.00$361.4017.60%12.79%
Sep 23, 2024Eun YangJefferies$432.00$353.0022.38%14.65%
Aug 28, 2024Hartaj SinghOppenheimer$575.00$362.4458.64%52.60%
Jul 08, 2024Ashwani VermaUBS$370.00$317.1816.65%-1.80%
Jun 12, 2024Tiago FauthWells Fargo$350.00$275.7626.92%-7.11%
May 02, 2024Hartaj SinghOppenheimer$400.00$255.1456.78%6.16%
Feb 12, 2024Chris ShibutaniGoldman Sachs$215.00$214.740.12%-42.94%
Jan 11, 2023-Argus Research$300.00$263.4113.89%-20.38%
Dec 06, 2022-Morgan Stanley$330.00$276.0719.53%-12.42%
Row per page
Go to

The latest United Therapeutics stock forecast, released on Oct 31, 2024 by Jasper Hellweg from Argus Research, set a price target of $400.00, which represents a 10.39% increase from the stock price at the time of the forecast ($362.36), and a 6.16% increase from UTHR last price ($376.80).

United Therapeutics Price Target by Period


1M3M12M
# Anlaysts248
Avg Price Target$412.50$458.00$395.88
Last Closing Price$376.80$376.80$376.80
Upside/Downside9.47%21.55%5.06%

In the current month, the average price target of United Therapeutics stock is $412.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 9.47% increase as opposed to United Therapeutics's last price of $376.80. This month's average price target is down -9.93% compared to last quarter, and up 4.20% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024H.C. WainwrightBuyBuyHold
Oct 21, 2024Wells FargoBuyBuyHold
Oct 21, 2024OppenheimerUnderperformUnderperformHold
Oct 21, 2024Cowen & Co.BuyBuyHold
Sep 23, 2024Wells FargoBuyBuyHold
Sep 23, 2024UBSUnderperformUnderperformHold
Sep 23, 2024JefferiesBuyBuyHold
Aug 28, 2024OppenheimerOutperformOutperformHold
Aug 20, 2024UBSUnderperformUnderperformHold
Aug 20, 2024Wells FargoBuyBuyHold
Row per page
Go to

United Therapeutics's last stock rating was published by H.C. Wainwright on Oct 31, 2024. The company gave UTHR a "Buy" rating, the same as its previous rate.

United Therapeutics Financial Forecast


United Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$609.40M-$506.90M$491.50M$516.00M$466.90M$461.90M$415.20M$444.70M$446.50M$379.10M$384.60M$380.10M$362.00M$356.30M$311.10M$401.50M$373.60M$362.60M$389.20M$370.50M
Avg Forecast$840.42M$831.46M$800.05M$757.42M$739.92M$722.62M$691.87M$620.31M$575.01M$585.82M$524.18M$514.37M$519.21M$493.21M$461.06M$420.06M$427.59M$421.45M$378.56M$368.95M$362.04M$358.46M$339.98M$344.33M$357.77M$337.60M$332.15M$335.43M$245.96M$315.26M
High Forecast$887.75M$878.29M$845.12M$769.81M$818.78M$724.84M$691.87M$620.31M$610.36M$603.74M$553.70M$543.34M$548.45M$493.21M$461.06M$420.06M$427.59M$421.45M$378.56M$368.95M$362.04M$358.46M$339.98M$344.33M$357.77M$337.60M$332.15M$335.43M$295.15M$378.31M
Low Forecast$803.20M$794.63M$764.62M$745.01M$681.30M$720.39M$691.87M$620.31M$538.02M$561.00M$500.96M$491.59M$496.21M$493.21M$461.06M$420.06M$427.59M$421.45M$378.56M$368.95M$362.04M$358.46M$339.98M$344.33M$357.77M$337.60M$332.15M$335.43M$196.77M$252.21M
# Analysts1113945481099888899999889127781612
Surprise %---------1.04%-0.99%0.95%1.05%1.01%1.10%0.97%1.06%1.18%1.03%1.06%1.06%1.06%1.03%0.87%1.19%1.12%1.08%1.58%1.18%

United Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $575.01M, with a low forecast of $538.02M, and a high forecast of $610.36M. UTHR's average Quarter revenue forecast represents a -5.64% decrease compared to the company's last Quarter revenue of $609.40M (Sep 23).

United Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113945481099888899999889127781612
EBITDA---------$327.00M-$319.00M$191.10M$334.60M$169.50M$327.60M$157.80M$221.40M$233.60M$49.60M$-117.50M$235.70M$152.10M$192.20M$90.80M$191.30M$273.00M$-630.00M$319.50M$272.30M
Avg Forecast$309.02M$305.72M$294.17M$278.50M$272.07M$265.70M$254.40M$106.50M$211.43M$215.40M$192.74M$96.82M$237.51M$181.35M$169.53M$88.02M$157.22M$154.96M$139.19M$80.02M$133.12M$131.80M$125.01M$166.34M$131.55M$124.13M$122.13M$-3.44B$146.77M$224.59M
High Forecast$326.42M$322.94M$310.74M$283.05M$301.06M$266.52M$254.40M$127.80M$224.43M$221.99M$203.59M$116.19M$285.01M$181.35M$169.53M$105.62M$157.22M$154.96M$139.19M$96.02M$133.12M$131.80M$125.01M$199.61M$131.55M$124.13M$122.13M$-2.75B$176.12M$269.50M
Low Forecast$295.33M$292.18M$281.15M$273.93M$250.51M$264.88M$254.40M$85.20M$197.82M$206.28M$184.20M$77.46M$190.00M$181.35M$169.53M$70.42M$157.22M$154.96M$139.19M$64.01M$133.12M$131.80M$125.01M$133.07M$131.55M$124.13M$122.13M$-4.13B$117.42M$179.67M
Surprise %---------1.52%-3.29%0.80%1.85%1.00%3.72%1.00%1.43%1.68%0.62%-0.88%1.79%1.22%1.16%0.69%1.54%2.24%0.18%2.18%1.21%

8 analysts predict UTHR's average Quarter EBITDA for Dec 23 to be $211.43M, with a high of $224.43M and a low of $197.82M. This is -35.34% lower than United Therapeutics's previous annual EBITDA (Sep 23) of $327.00M.

United Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113945481099888899999889127781612
Net Income---------$267.60M-$240.90M$132.10M$239.30M$116.00M$239.90M$112.20M$162.70M$172.60M$28.30M$98.00M$171.20M$107.10M$137.70M$52.60M$132.40M$205.10M$-494.60M$244.50M$178.60M
Avg Forecast$377.84M$400.87M$384.30M$351.67M$318.94M$315.73M$314.86M$60.77M$202.66M$246.93M$221.14M$55.24M$168.87M$185.70M$208.49M$50.22M$170.05M$170.64M$143.45M$45.66M$140.18M$134.96M$131.71M$119.17M$125.45M$120.65M$117.74M$-2.70B$112.32M$147.30M
High Forecast$405.51M$430.23M$412.44M$353.28M$387.11M$315.82M$315.36M$72.92M$256.43M$275.61M$237.33M$66.29M$202.65M$185.70M$208.49M$60.27M$170.05M$170.64M$143.45M$54.79M$140.18M$134.96M$131.71M$143.01M$125.45M$120.65M$117.74M$-2.16B$134.78M$176.77M
Low Forecast$356.09M$377.79M$362.17M$350.07M$262.94M$315.64M$314.37M$48.61M$153.55M$194.92M$208.41M$44.19M$135.10M$185.70M$208.49M$40.18M$170.05M$170.64M$143.45M$36.52M$140.18M$134.96M$131.71M$95.34M$125.45M$120.65M$117.74M$-3.24B$89.85M$117.84M
Surprise %---------1.08%-4.36%0.78%1.29%0.56%4.78%0.66%0.95%1.20%0.62%0.70%1.27%0.81%1.16%0.42%1.10%1.74%0.18%2.18%1.21%

United Therapeutics's average Quarter net income forecast for Dec 23 is $202.66M, with a range of $153.55M to $256.43M. UTHR's average Quarter net income forecast represents a -24.27% decrease compared to the company's last Quarter net income of $267.60M (Sep 23).

United Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113945481099888899999889127781612
SG&A---------$127.60M-$87.30M$166.10M$98.40M$141.50M$79.00M$127.90M$109.10M$112.80M$117.20M$103.80M$66.30M$105.90M$93.00M$105.20M$99.40M$39.60M$92.00M$-6.60M$56.40M
Avg Forecast$210.34M$208.10M$200.24M$189.57M$185.19M$180.86M$173.16M$251.66M$143.91M$146.62M$131.19M$228.78M$192.50M$123.44M$115.39M$207.98M$107.02M$105.48M$94.75M$189.07M$90.61M$89.72M$85.09M$80.49M$89.54M$84.50M$83.13M$83.95M$-3.03M$46.52M
High Forecast$222.19M$219.82M$211.52M$192.67M$204.92M$181.41M$173.16M$301.99M$152.76M$151.10M$138.58M$274.54M$231.00M$123.44M$115.39M$249.58M$107.02M$105.48M$94.75M$226.89M$90.61M$89.72M$85.09M$96.58M$89.54M$84.50M$83.13M$83.95M$-2.43M$55.82M
Low Forecast$201.02M$198.88M$191.37M$186.46M$170.52M$180.30M$173.16M$201.33M$134.65M$140.41M$125.38M$183.02M$154.00M$123.44M$115.39M$166.39M$107.02M$105.48M$94.75M$151.26M$90.61M$89.72M$85.09M$64.39M$89.54M$84.50M$83.13M$83.95M$-3.64M$37.21M
Surprise %---------0.87%-0.38%0.86%0.80%1.23%0.38%1.20%1.03%1.19%0.62%1.15%0.74%1.24%1.16%1.17%1.18%0.48%1.10%2.18%1.21%

United Therapeutics's average Quarter SG&A projection for Dec 23 is $143.91M, based on 8 Wall Street analysts, with a range of $134.65M to $152.76M. The forecast indicates a 12.78% rise compared to UTHR last annual SG&A of $127.60M (Sep 23).

United Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113945481099888899999889127781612
EPS---------$5.71-$5.20$2.88$5.26$2.56$5.31$2.49$3.62$3.85$0.63$2.22$3.86$2.43$3.14$1.20$3.02$4.68$-11.32$5.65$4.01
Avg Forecast$7.81$8.28$7.94$7.27$6.59$6.52$6.51$5.74$4.19$5.10$4.57$4.59$4.72$3.91$4.39$3.65$3.58$3.59$3.02$3.03$2.95$2.84$2.77$2.74$2.64$2.54$2.48$2.72$1.62$2.73
High Forecast$8.38$8.89$8.52$7.30$8.00$6.53$6.52$5.76$5.30$5.69$4.90$4.92$5.07$3.91$4.39$3.65$3.58$3.59$3.02$3.03$2.95$2.84$2.77$2.74$2.64$2.54$2.48$2.72$1.94$3.28
Low Forecast$7.36$7.81$7.48$7.23$5.43$6.52$6.50$5.72$3.17$4.03$4.31$4.32$4.45$3.91$4.39$3.65$3.58$3.59$3.02$3.03$2.95$2.84$2.77$2.74$2.64$2.54$2.48$2.72$1.29$2.18
Surprise %---------1.12%-1.13%0.61%1.35%0.58%1.46%0.70%1.01%1.27%0.21%0.75%1.36%0.88%1.15%0.45%1.19%1.89%-4.17%3.49%1.47%

According to 8 Wall Street analysts, United Therapeutics's projected average Quarter EPS for Dec 23 is $4.19, with a low estimate of $3.17 and a high estimate of $5.30. This represents a -26.67% decrease compared to UTHR previous annual EPS of $5.71 (Sep 23).

United Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$2.15$33.861474.88%Buy
LRMRLarimar Therapeutics$7.57$20.33168.56%Buy
APLSApellis Pharmaceuticals$28.56$76.13166.56%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
RAREUltragenyx Pharmaceutical$51.06$108.14111.79%Buy
REPLReplimune Group$12.02$24.20101.33%Buy
LEGNLegend Biotech$43.61$82.6289.45%Buy
KNSAKiniksa Pharmaceuticals$21.48$36.3369.13%Buy
MNKDMannKind$7.09$11.0055.15%Buy
ASNDAscendis Pharma$125.77$190.2151.24%Buy
AKROAkero Therapeutics$32.05$46.0043.53%Buy
BGNEBeiGene$207.25$255.8023.43%Buy
NUVLNuvalent$89.53$107.8320.44%Buy
BPMCBlueprint Medicines$91.88$109.7119.41%Buy
PCVXVaxcyte$106.49$124.1416.57%Buy
INCYIncyte$75.75$84.5611.63%Buy
UTHRUnited Therapeutics$376.80$358.20-4.94%Buy
ALNYAlnylam Pharmaceuticals$269.95$254.21-5.83%Buy

UTHR Forecast FAQ


Yes, according to 7 Wall Street analysts, United Therapeutics (UTHR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of UTHR's total ratings.

United Therapeutics (UTHR) average price target is $358.2 with a range of $215 to $575, implying a -4.94% from its last price of $376.8. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for UTHR stock, the company can go down by -4.94% (from the last price of $376.8 to the average price target of $358.2), up by 52.60% based on the highest stock price target, and down by -42.94% based on the lowest stock price target.

UTHR's average twelve months analyst stock price target of $358.2 does not support the claim that United Therapeutics can reach $600 in the near future.

2 Wall Street analysts forecast a $412.5 price target for United Therapeutics (UTHR) this month, up 9.47% from its last price of $376.8. Compared to the last 3 and 12 months, the average price target increased by 21.55% and increased by 5.06%, respectively.

United Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.77B (high $2.86B, low $2.71B), average EBITDA is $898.67M (high $949.78M, low $854.99M), average net income is $1.01B (high $1.09B, low $941.56M), average SG&A $790.86M (high $861.49M, low $725.3M), and average EPS is $25.36 (high $26.8, low $24.17). UTHR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.23B (high $3.38B, low $3.11B), average EBITDA is $1.19B (high $1.24B, low $1.14B), average net income is $1.51B (high $1.6B, low $1.45B), average SG&A $808.24M (high $846.19M, low $777.73M), and average EPS is $31.3 (high $33.09, low $29.88).

Based on United Therapeutics's last annual report (Dec 2022), the company's revenue was $1.94B, beating the average analysts forecast of $1.89B by 2.26%. Apple's EBITDA was $984.7M, beating the average prediction of $676.4M by 45.58%. The company's net income was $727.3M, beating the average estimation of $613.29M by 18.59%. Apple's SG&A was $487M, missing the average forecast of $639.32M by -23.83%. Lastly, the company's EPS was $15.98, missing the average prediction of $16.67 by -4.13%. In terms of the last quarterly report (Sep 2023), United Therapeutics's revenue was $609.4M, beating the average analysts' forecast of $585.82M by 4.03%. The company's EBITDA was $327M, beating the average prediction of $215.4M by 51.81%. United Therapeutics's net income was $267.6M, beating the average estimation of $246.93M by 8.37%. The company's SG&A was $127.6M, missing the average forecast of $146.62M by -12.97%. Lastly, the company's EPS was $5.71, beating the average prediction of $5.1 by 11.92%